Acute Whey Protein And Casein Supplementation: Effect On Protein Metabolism After Resistance Exercise

Protein Supplementation Clinical Trial

Official title:

Association of Whey Protein and Casein in the Same Proportions of Human Breast Milk Promoted Similar Branched-chain Amino Acids Profile and Reduced Delayed Muscle Soreness in Physically Active Man

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04648384
• Other study ID #: Protein Supplementation
• Status: Completed
• Phase: N/A
• Start date: March 20, 2016
• Est. completion date: October 20, 2019

Study information

• Verified date: November 2020
• Source: University of Sao Paulo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proteins of human breast milk are the most important endocrine signaling system that promotes neonatal growth by increasing the release of insulin, insulin-like growth factor-1 (IGF-1), and the leucine-mediated mammalian target of rapamycin complex 1- (mTORC1) signaling of pancreatic β-cells. Remarkably, the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine are involved in the growth-promoting effects of milk, protein biosynthesis, and metabolism because they physiologically stimulate insulin secretion The present study sought to investigate the effects of the combination of whey protein and casein in the ratio of 80:20 ("whey protein: casein" or "casein: whey protein") as breast milk proportion on the peak and the period of the permanence of branched-chain amino acids in the blood circulation, final metabolites of protein metabolism and delayed onset muscle soreness (DOMS) after a single bout of fasting or a resistance exercise session.

Description:

The present study investigated the effects of the association of WP and casein in the ratio of 80:20, a similar ratio of human breast milk, on blood branched-chain amino acids (BCAAs) profile by HPLC technique, markers of protein metabolism (creatinine, urea, and urine nitrogen) and delayed onset muscle soreness (DOMS) after a single bout of resistance exercise. A double-blind, crossover and acute study was conducted with ten men (age 29 ± 8 y; BMI: 25.4 ± 2.9 Kg/m2; 77 ± 12 kg; 1.74 ± 0.09 m) that were randomly assigned to five supplementation treatments: WP - whey protein; CAS - casein; WP/CAS - 80% WP/20% CAS; CAS/WP - 80% CAS/ 20% WP; PLA - placebo. Participants were submitted to the following evaluations: performance sessions, blood collection for each session for the BCAAs profile determination, two food records, 3-days assessment of DOMS (24h, 48h, 72h) after each treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: October 20, 2019
• Est. primary completion date: July 20, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy
• practice resistance training at least 3x a week

Exclusion Criteria:

• Smokers
• Muscle injures
• cardiovascular diseases
• Diabetes mellitus
• Lactose intolerance

Related Conditions & MeSH terms

• Protein Supplementation
• Sports Nutrition

Intervention

Dietary Supplement:
• Blend Protein Supplementation
Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
• Placebo Supplementation
Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition

Other:
• Resistance Exercise
10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise

Locations

Country	Name	City	State
Brazil	University of São Paulo, School of Physical Education and Sports of Ribeirão Preto.	Ribeirão Preto	São Paulo

Sponsors (4)

Lead Sponsor	Collaborator
University of Sao Paulo	Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Fundação de Amparo à Pesquisa do Estado de São Paulo, Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in plasma amino acids concentration	Blood sample collected for analysis of BCAA concentration after blend protein or placebo supplementation expressed in (µmol/L)	5 weeks
Primary	Change from baseline in 1RM test	Change of training load using RPE, time and load expressed in (a.u)	5 weeks
Primary	Change in protein metabolism	Change in nitrogen excretion, and nitrogen balance after protein supplementation expressed in (g/24 hours)	5 weeks
Primary	Changes from baseline in macronutrient intake	Change of macronutrient intake were calculated pre and post treatment expressed in (g/24 hours)	5 weeks
Primary	Change in delayed onset muscle soreness	Change from baseline the delayed onset muscle soreness pre, post, 24 hours, 48 hours and 72 hours after treatment expressed in (a.u)	5 weeks